Abstract
Tumor necrosis factor receptor-associated factor (TRAF) is an important binding protein of tumor necrosis factor (TNF) superfamily and the toll/IL-1 receptor (TIR) superfamily, which play an important role in innate immunity and acquired immunity. TRAFs family have 7 members (TRAF1-7), and TRAF6 has its special facture and biological function. TRAF6 has two special domains: C-terminal domain and N-terminal domain, which could integrate with multiple kinases and regulate signaling pathway function as an E3 ubiquitin ligase. Studies have increasingly found that TRAF6 is closely related to central nervous system diseases, such as stroke, Traumatic brain injury, neurodegenerative diseases and neuropathic pain. Further research on the pathophysiological mechanism may be expected to become the new targets for the treatment of central nervous system diseases.
Keywords: TRAF6, E3 ubiquitin ligase, ubiquitination, inflammation, ROS, central nervous system diseases.
Graphical Abstract
Current Neuropharmacology
Title:Roles of TRAF6 in Central Nervous System
Volume: 16 Issue: 9
Author(s): Yang Dou, Xiaodi Tian, Jian Zhang, Zhong Wang and Gang Chen*
Affiliation:
- Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006,China
Keywords: TRAF6, E3 ubiquitin ligase, ubiquitination, inflammation, ROS, central nervous system diseases.
Abstract: Tumor necrosis factor receptor-associated factor (TRAF) is an important binding protein of tumor necrosis factor (TNF) superfamily and the toll/IL-1 receptor (TIR) superfamily, which play an important role in innate immunity and acquired immunity. TRAFs family have 7 members (TRAF1-7), and TRAF6 has its special facture and biological function. TRAF6 has two special domains: C-terminal domain and N-terminal domain, which could integrate with multiple kinases and regulate signaling pathway function as an E3 ubiquitin ligase. Studies have increasingly found that TRAF6 is closely related to central nervous system diseases, such as stroke, Traumatic brain injury, neurodegenerative diseases and neuropathic pain. Further research on the pathophysiological mechanism may be expected to become the new targets for the treatment of central nervous system diseases.
Export Options
About this article
Cite this article as:
Dou Yang , Tian Xiaodi , Zhang Jian, Wang Zhong and Chen Gang *, Roles of TRAF6 in Central Nervous System, Current Neuropharmacology 2018; 16 (9) . https://dx.doi.org/10.2174/1570159X16666180412094655
DOI https://dx.doi.org/10.2174/1570159X16666180412094655 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Mechanisms of Developing Post-Traumatic Stress Disorder: New Targets for Drug Development and Other Potential Interventions
CNS & Neurological Disorders - Drug Targets Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Editorial (Thematic Issue: New Therapeutic Targets in Clinical Medicine)
Current Pharmaceutical Design Update on Alzheimer’s Disease Therapeutics
Reviews on Recent Clinical Trials Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Anti-inflammatory Activity of Extra Virgin Olive Oil Polyphenols: Which Role in the Prevention and Treatment of Immune-Mediated Inflammatory Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Cerebral Malaria on Brain Distribution of Mefloquine
Drug Metabolism Letters Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study
Current Alzheimer Research Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
Current Medicinal Chemistry Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Elaboration of New Anti-Inflammatory Agents Using Pharmacophore Based 3D QSAR of 4, 5-Diaryl Imidazoline as P2X7 Receptor Antagonists
Letters in Drug Design & Discovery Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry Central Nervous System Agents for Ischemic Stroke: Neuroprotection Mechanisms
Central Nervous System Agents in Medicinal Chemistry Neuroglobin and Estrogen Receptors: A New Pathway of Cell Survival and Cell Death Balance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Medicinal Chemistry Perspective of Fused Isoxazole Derivatives
Current Topics in Medicinal Chemistry Conference Report: 182nd AAAS Annual Meeting, Washington DC, February 11-15, 2016
CNS & Neurological Disorders - Drug Targets Hematopoietic Colony Stimulating Factors in Cardiovascular and Pulmonary Remodeling: Promoters or Inhibitors?
Current Pharmaceutical Design Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry <i>Lantana undulata</i> Schrank – A New Source of Biological Potential in the Verbenaceae Family
The Natural Products Journal